Related Experiment Video
Updated: Mar 20, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.5K
Dystrophin-Deficient Cardiomyopathy
Forum Kamdar1, Daniel J Garry1
1Cardiovascular Division, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota.
Journal of the American College of Cardiology
|May 28, 2016
Summary
Dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, often involve heart muscle. Early cardiovascular monitoring and therapies are crucial for managing cardiomyopathy in these neuromuscular diseases.
Area of Science:
- Neurology
- Cardiology
- Genetics
Background:
- Dystrophinopathies are inherited neuromuscular disorders caused by mutations in the dystrophin gene.
- These conditions primarily manifest as skeletal muscle weakness but frequently involve cardiac muscle, leading to cardiomyopathy.
- Cardiomyopathy is a significant contributor to morbidity and mortality in dystrophinopathy patients.
Purpose of the Study:
- To review the pathophysiology of cardiomyopathy in dystrophinopathies.
- To discuss the cardiac involvement and manifestations in patients with Duchenne muscular dystrophy and Becker muscular dystrophy.
- To outline current and potential treatment strategies for dystrophinopathy-associated cardiomyopathy.
Main Methods:
- Literature review focusing on pathophysiology, clinical presentation, and therapeutic interventions.
- Analysis of recent studies and clinical guidelines regarding cardiovascular care in dystrophinopathies.
- Synthesis of information on genetic basis, cardiac effects, and management approaches.
Main Results:
- Cardiomyopathy is a common and serious complication of dystrophinopathies, affecting both males and female carriers.
- Early cardiovascular screening, including annual imaging, is recommended for affected individuals.
- Advanced therapies may benefit patients with end-stage heart failure due to Duchenne muscular dystrophy or Becker muscular dystrophy.
Conclusions:
- Cardiomyopathy requires close monitoring and specialized cardiovascular care in patients with dystrophinopathies.
- Timely intervention and consideration of advanced therapies can improve outcomes for affected individuals.
- Understanding the cardiac implications is vital for comprehensive management of these neuromuscular diseases.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
728
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
728
01:25Cardiomyopathy I: Introduction and Classification
775
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
775
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
643
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
643
01:21Satellite Stem Cells and Muscular Dystrophy
2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
751
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
751
01:29Cardiomyopathy V: Interprofessional Care
605
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605